London: Scientists have discovered a new drug which they say can add an extra five months to life of men with advanced prostate cancer when chemotherapy fails.
British researchers found in trials that men taking the drug `enzalutamide` survived for more than 18 months compared with less than 14 months for those on a placebo, a newspaper reported.
Almost half of those receiving the new drug had a better quality of life.
Enzalutamide, which was developed by British scientists at the Institute of Cancer Research (ICR) and the Royal Marsden Hospital, in London, is one of four discoveries in the past two years that significantly extend life.
"Advanced prostate cancer is extremely difficult to treat, and it`s taken a massive co-ordinated effort to finally bring new drugs into the pipeline, after decades where there were no options once old-style hormone treatment stopped working," Professor Alan Ashworth, chief executive of the ICR, said.
In the study nearly 1,200 patients were given enzalutamide following chemotherapy. Survival for those taking the new drug was 18.4 months on average, compared with 13.6 months for those on a placebo.
About 43 per cent of men on enzalutamide reported an improved quality of life, compared with 18 per cent of the placebo group.
The drug could be licensed for use by British patients early next year. The cost is not yet known.
The study was published in the New England Journal of Medicine.
PTI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.